ZA9711239B - OB fusion protein compositions and methods. - Google Patents

OB fusion protein compositions and methods.

Info

Publication number
ZA9711239B
ZA9711239B ZA9711239A ZA9711239A ZA9711239B ZA 9711239 B ZA9711239 B ZA 9711239B ZA 9711239 A ZA9711239 A ZA 9711239A ZA 9711239 A ZA9711239 A ZA 9711239A ZA 9711239 B ZA9711239 B ZA 9711239B
Authority
ZA
South Africa
Prior art keywords
methods
fusion protein
protein compositions
compositions
fusion
Prior art date
Application number
ZA9711239A
Other languages
English (en)
Inventor
Michael B Mann
Randy I Hecht
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of ZA9711239B publication Critical patent/ZA9711239B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
ZA9711239A 1996-12-20 1997-12-15 OB fusion protein compositions and methods. ZA9711239B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US77097396A 1996-12-20 1996-12-20

Publications (1)

Publication Number Publication Date
ZA9711239B true ZA9711239B (en) 1998-06-23

Family

ID=25090296

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA9711239A ZA9711239B (en) 1996-12-20 1997-12-15 OB fusion protein compositions and methods.

Country Status (26)

Country Link
EP (2) EP0954588B1 (es)
JP (2) JP4175668B2 (es)
KR (1) KR100937550B1 (es)
CN (1) CN1195858C (es)
AR (2) AR009436A1 (es)
AT (1) ATE351910T1 (es)
AU (1) AU5606098A (es)
BG (1) BG64288B1 (es)
BR (1) BR9713755A (es)
CA (1) CA2275183A1 (es)
CZ (1) CZ298203B6 (es)
DE (1) DE69737266T2 (es)
DK (1) DK0954588T3 (es)
EA (2) EA004790B1 (es)
ES (1) ES2280083T3 (es)
HK (1) HK1021388A1 (es)
HU (1) HU227088B1 (es)
IL (1) IL130396A (es)
NO (2) NO324506B1 (es)
NZ (1) NZ514145A (es)
PL (1) PL194159B1 (es)
PT (1) PT954588E (es)
RS (1) RS49927B (es)
SK (1) SK287578B6 (es)
WO (1) WO1998028427A1 (es)
ZA (1) ZA9711239B (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6936439B2 (en) 1995-11-22 2005-08-30 Amgen Inc. OB fusion protein compositions and methods
ES2217327T3 (es) * 1995-11-22 2004-11-01 Amgen Inc., Proteina ob para aumentar la masa de tejido magro.
US20030040467A1 (en) 1998-06-15 2003-02-27 Mary Ann Pelleymounter Ig/ob fusions and uses thereof.
US6620413B1 (en) 1995-12-27 2003-09-16 Genentech, Inc. OB protein-polymer chimeras
US6541604B1 (en) 1996-01-08 2003-04-01 Genentech, Inc. Leptin receptor having a WSX motif
US7074397B1 (en) 1996-01-08 2006-07-11 Genentech, Inc. Method for enhancing proliferation or differentiation of a cell using ob protein
US20020019352A1 (en) * 1997-04-17 2002-02-14 David N. Brems Stable, active, human ob protein compositions and methods
CA2286098C (en) * 1997-04-17 2009-07-07 Amgen Inc. Compositions comprising conjugates of stable, active, human ob protein with antibody fc chain and methods
IL138214A0 (en) 1998-03-09 2001-10-31 Zealand Pharmaceuticals As Pharmacolgically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
US6420339B1 (en) 1998-10-14 2002-07-16 Amgen Inc. Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
SI2319928T1 (sl) 1998-10-23 2013-08-30 Kirin-Amgen, Inc. Dimerni trombopoietinski peptidni mimetiki, ki se veĺ˝ejo na receptor mp1 in imajo trombopoietinsko aktivnost
US7488590B2 (en) 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
US8106098B2 (en) 1999-08-09 2012-01-31 The General Hospital Corporation Protein conjugates with a water-soluble biocompatible, biodegradable polymer
US6808902B1 (en) 1999-11-12 2004-10-26 Amgen Inc. Process for correction of a disulfide misfold in IL-1Ra Fc fusion molecules
MXPA02010351A (es) * 2000-04-21 2003-04-25 Amgen Inc Antagonistas de integrina/adhesion.
US20020090646A1 (en) * 2000-05-03 2002-07-11 Amgen Inc. Calcitonin-related molecules
US6677136B2 (en) * 2000-05-03 2004-01-13 Amgen Inc. Glucagon antagonists
ES2309167T3 (es) 2001-02-19 2008-12-16 Merck Patent Gmbh Metodo para identificar epitotes de celulas t y metodo para preparar moleculas con inmunogenicidad reducida.
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
JP2002306163A (ja) * 2001-04-11 2002-10-22 Chemo Sero Therapeut Res Inst 大腸菌を宿主とする遺伝子組換えヒトトロンビンの調製方法
DK1444516T3 (da) 2001-10-22 2010-11-15 Amgen Inc Anvendelse af leptin til behandling af lipoatrofi hos mennesker og fremgangsmåde til at bestemme en prædisposition for denne behandling
NZ534757A (en) 2002-03-12 2006-07-28 Merck & Co Inc Substituted amides
US20030191056A1 (en) 2002-04-04 2003-10-09 Kenneth Walker Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins
JP3936673B2 (ja) * 2003-06-02 2007-06-27 国立大学法人群馬大学 Ｃｄ４７部分ペプチドと抗ｓｈｐｓ−１モノクロナール抗体
US8420087B2 (en) 2004-01-05 2013-04-16 Antisoma Research Limited Interleukin-12 targeted to oncofoetal fibronectin
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
CA2555894A1 (en) 2004-02-11 2005-08-25 Amylin Pharmaceuticals, Inc. Pancreatic polypeptide family motifs and polypeptides comprising the same
EP1773400A2 (en) 2004-07-08 2007-04-18 Amgen Inc. Therapeutic peptides
US7732131B2 (en) 2004-08-03 2010-06-08 Innate Pharma S.A. Therapeutic and diagnostic methods and compositions targeting 4Ig-B7-H3 and its counterpart NK cell receptor
US8394765B2 (en) 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
ES2325773T5 (es) 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
CN101296942A (zh) * 2005-08-11 2008-10-29 安米林药品公司 具有可选择特性的杂合多肽
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
AU2006303440B2 (en) 2005-10-21 2011-09-08 F. Hoffmann-La Roche Ag Method for the recombinant expression of a polypeptide
DOP2007000020A (es) 2006-01-31 2007-09-15 Bayer Schering Pharma Ag Modulación de la actividad de mdl-1 para el tratamiento de enfermedades inflamatorias
WO2009149379A2 (en) 2008-06-05 2009-12-10 Regents Of The University Of Michigan Use of leptin for the treatment of fatty liver diseases and conditions
KR20120030383A (ko) 2009-04-22 2012-03-28 메르크 파텐트 게엠베하 변형된 ＦｃＲｎ 결합 자리를 갖는 항체 융합 단백질
EP3135294B1 (en) 2009-08-14 2020-06-03 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Use of il-15-il-15 receptor heterodimers to treat lymphopenia
ES2630031T3 (es) 2010-09-28 2017-08-17 Aegerion Pharmaceuticals, Inc. Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada
DK2729160T3 (da) 2011-07-08 2019-07-01 Aegerion Pharmaceuticals Inc Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet
EP2764565B1 (en) 2011-10-05 2023-02-22 OneD Material, Inc. Silicon nanostructure active materials for lithium ion batteries and processes, compositions, components, and devices related thereto
LT2900230T (lt) 2012-09-27 2019-01-10 The Children`S Medical Center Corporation Junginiai, skirti nutukimo gydymui ir jų panaudojimo būdai
TR201901299T4 (tr) 2013-11-26 2019-02-21 Childrens Medical Ct Corp Obezite tedavisine yönelik bileşikler ve bunların kullanım yöntemleri.
US20170209408A1 (en) 2014-04-03 2017-07-27 The Children's Medical Center Corporation Hsp90 inhibitors for the treatment of obesity and methods of use thereof
PT3509624T (pt) 2016-09-12 2023-08-28 Amryt Pharmaceuticals Inc Métodos de deteção de anticorpos neutralizantes anti-leptina
CN110183530A (zh) * 2019-06-21 2019-08-30 深圳市亚辉龙生物科技股份有限公司 瘦素免疫原、杂交瘤细胞、单克隆抗体、多克隆抗体及应用
CN112618698B (zh) * 2019-10-08 2021-10-08 北京东方百泰生物科技股份有限公司 一种人白细胞介素10-Fc融合蛋白的注射制剂

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
CZ25697A3 (en) * 1994-07-29 1997-09-17 Smithkline Beecham Plc Novel compounds
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
JPH0870875A (ja) * 1994-09-05 1996-03-19 Tosoh Corp 組換えアルカリフォスファタ−ゼ融合タンパク質
GB9511935D0 (en) * 1995-06-13 1995-08-09 Smithkline Beecham Plc Novel compound
ES2217327T3 (es) * 1995-11-22 2004-11-01 Amgen Inc., Proteina ob para aumentar la masa de tejido magro.
RU2178307C2 (ru) * 1995-12-27 2002-01-20 Джинентех Инк. Производные ов-протеина

Also Published As

Publication number Publication date
CA2275183A1 (en) 1998-07-02
JP2008289487A (ja) 2008-12-04
PL194159B1 (pl) 2007-05-31
DK0954588T3 (da) 2007-05-14
ATE351910T1 (de) 2007-02-15
BG103522A (en) 2000-03-31
WO1998028427A1 (en) 1998-07-02
EP1835030A1 (en) 2007-09-19
AR059907A2 (es) 2008-05-07
HK1021388A1 (en) 2000-06-09
BR9713755A (pt) 2000-02-01
EP0954588A1 (en) 1999-11-10
HUP0000302A3 (en) 2005-12-28
EA200100216A1 (ru) 2001-08-27
ES2280083T3 (es) 2007-09-01
IL130396A (en) 2011-09-27
PT954588E (pt) 2007-03-30
CZ9902036A3 (cs) 2000-10-11
PL334242A1 (en) 2000-02-14
DE69737266T2 (de) 2007-11-08
KR100937550B1 (ko) 2010-01-19
YU27999A (sh) 2000-10-30
SK77499A3 (en) 2001-04-09
AU5606098A (en) 1998-07-17
HU227088B1 (en) 2010-06-28
AR009436A1 (es) 2000-04-12
NO20071415L (no) 1999-08-19
JP4659068B2 (ja) 2011-03-30
IL130396A0 (en) 2000-06-01
EA199900575A1 (ru) 2000-02-28
CN1246154A (zh) 2000-03-01
NO324506B1 (no) 2007-11-05
EA004791B1 (ru) 2004-08-26
NO325096B1 (no) 2008-02-04
NZ514145A (en) 2003-08-29
CZ298203B6 (cs) 2007-07-18
SK287578B6 (sk) 2011-03-04
DE69737266D1 (de) 2007-03-08
JP2001512417A (ja) 2001-08-21
EA004790B1 (ru) 2004-08-26
CN1195858C (zh) 2005-04-06
NO992779D0 (no) 1999-06-08
HUP0000302A2 (hu) 2000-06-28
NO992779L (no) 1999-08-19
KR20000069617A (ko) 2000-11-25
JP4175668B2 (ja) 2008-11-05
RS49927B (sr) 2008-09-29
EP0954588B1 (en) 2007-01-17
BG64288B1 (bg) 2004-08-31

Similar Documents

Publication Publication Date Title
ZA9711239B (en) OB fusion protein compositions and methods.
HUP0200414A2 (en) Interferon-betha fusion proteins and uses
ZA964733B (en) Ob protein compositions and methods
GB9718609D0 (en) Fusion protein
AU1226297A (en) Basic protein composition, basic peptide composition and application thereof
PL331765A1 (en) Trnsplant prosthesis, materials and methods
AU4922497A (en) Interleukin-18-receptor proteins
AU3562299A (en) Inhibin-hbc fusion protein
HUP0100535A3 (en) Hydrophobically-modified protein compositions and methods
ZA989400B (en) Method and composition
AU6721696A (en) Cd44-like protein
ZA9710338B (en) Proteins
EP1018551A4 (en) MEGSINE PROTEIN
AU3923000A (en) Agp-1 fusion protein compositions and methods
AU1952497A (en) Novel antibody-cytokine fusion protein, and methods of making and using the same
AU3640397A (en) Ob protein binding protein
IL125933A0 (en) Canine ob protein compositions and methods
AU1807399A (en) Cadherin-like polypeptides, methods and compositions related thereto
EP0915100A4 (en) NEW PROTEIN
ZA971900B (en) Modified proteins
ZA9811079B (en) Hydrophobically-modified protein compositions and methods.
AU1902999A (en) Hydrophobically-modified protein compositions and methods
ZA973709B (en) Proteins.
SI0877803T1 (sl) Receptor ob-proteina in sorodni sestavki in postopki
GB9611896D0 (en) Modified proteins